Leinco Technologies partnered with CellCarta to combine antibody portfolios for proteomics tools used in drug development and biomarker discovery. Leinco said the collaboration pairs its antibody library with CellCarta’s menu of CPTAC-derived antibodies used in Immuno-MRM, an approach that couples antibody-based protein enrichment with targeted mass spectrometry. The partnership targets immune-oncology and other therapeutic modalities, with the companies aiming to support protein biomarker discovery and clinical research. Leinco said the partnership will use antibodies validated through the US National Cancer Institute’s Clinical Proteomic Tumor Analysis Consortium (CPTAC). Financial terms were not disclosed, but Leinco said the combined offering is intended to improve data confidence and scalability for customers.